29 October 2024
This announcement contains
inside information as stipulated under the UK version of the Market
Abuse Regulation 596/2014 which is part of English Law by virtue of
the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this
information is considered to be in the public
domain.
BEXIMCO PHARMACEUTICALS
LIMITED
Notification of Preliminary
Results and Annual General Meeting
Beximco Pharmaceuticals Limited
("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI
No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical
ingredients, today announces information for shareholders of the
Company that the Board of Directors decided at their meeting held
on 28 October 2024. Please see further detail as
follows:
|
1.
|
To recommend the approval of the
Financial Statements for the year ended 30 June, 2024
|
The Audited Financial Statements for
the year ended 30 June 2024 have been approved. The full accounts
are expected to be announced by 7 November 2024
|
|
2.
|
Date & Time of
48th Annual General Meeting ("AGM") of the Company for the
year ended 30 June, 2024
|
29 December 2024 at 10.30 A.M.
Bangladesh Time
|
|
3.
|
Venue of AGM
|
Virtual Platform (Zoom
Meeting)
|
|
4.
|
Proposed Dividend for the year ended
30 June, 2024
|
40% Cash Dividend (i.e. Tk 4.00 per
Share)
|
|
5.
|
Record date
|
25 November 2024
|
|
6.
|
Proposed change of Company
name
|
Resolved to pass a Special
Resolution to change the name of the Company from "Beximco
Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" in
compliance to the Companies Act, 1994 (amended in 2020), subject to
the approval of the Shareholders in the 48th AGM of the Company to
be held on 29th December, 2024 as a matter of special
business
|
Comparative Financial Disclosures:
Beximco Pharmaceuticals
Limited and its Subsidiaries (Consolidated)
|
Particulars
|
Year ended
30 June
2024
|
Year ended
30 June
2023
|
|
Net Profit after Tax
|
Tk.
5,866,771,470
|
Tk.
4,524,468,490
|
|
Earnings Per Share (EPS)
|
Tk.
13.07
|
Tk.
10.34
|
|
Net Asset Value (NAV)
|
Tk.
47,949,964,744
|
Tk.
43,680,703,738
|
|
Net Asset Value per share
(NAVPS)
|
Tk.
107.48
|
Tk.
97.91
|
|
Net Operating Cash Flow Per Share
(NOCFPS)
|
Tk.
18.75
|
Tk.
13.64
|
Beximco Pharmaceuticals
Limited (Stand-alone)
|
Particulars
|
Year ended
30 June
2024
|
Year ended
30 June
2023
|
|
Net Profit after Tax
|
Tk. 5,610,513,429
|
Tk. 4,588,008,908
|
|
Earnings Per Share (EPS)
|
Tk.
12.58
|
Tk.
10.28
|
|
Net Asset Value (NAV)
|
Tk. 47,391,484,377
|
Tk. 43,341,239,142
|
|
Net Asset Value per share
(NAVPS)
|
Tk.
106.23
|
Tk. 97.15
|
|
Net Operating Cash Flow Per Share
(NOCFPS)
|
Tk.
17.46
|
Tk.
12.96
|
For
further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating
Officer
Tel: +880 2 58611001,
Ext.20111
Mohammad Ali Nawaz, Chief Financial
Officer
Tel: +880 2 58611001,
Ext.20030
SPARK Advisory Partners Limited (Nominated
Adviser)
Mark Brady / Andrew Emmott / Adam
Dawes
Tel: +44 (0) 20 3368 3551 /
3555
SP
Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI
Consulting
Simon Conway / Victoria Foster
Mitchell / Sam Purewal
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading
manufacturer and exporter of medicines based in Bangladesh. Since
its inception in 1976, the Company remains committed to health and
wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics
encompasses diverse delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, insulins, prefilled
syringes, injectables, nebuliser solutions, oral soluble films etc.
The Company also undertakes contract manufacturing for
multinational and leading global generic pharmaceutical
companies.
Beximco Pharma′s state-of-the-art
manufacturing facilities are certified by global regulatory
authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more
than 50 countries. More than 5700 employees are driving the company
towards achieving its aspiration to be among the most admired
companies in the world.
